Risankizumab|1612838-76-2|(Risankizumab rzaa; BI 655066)-陌孚医药/Medlife

您当前的位置：

Risankizumab (Synonyms: Risankizumab rzaa; BI 655066)

目录号: PL13350 纯度: ≥97%

CAS No. :1612838-76-2

商品编号	规格	价格	会员价
PL13350-1mg	1mg	¥10929.00	请登录
PL13350-5mg	5mg	¥23787.00	请登录
PL13350-10mg	10mg	询价	询价
PL13350-50mg	50mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Risankizumab
中文别名	利散吉珠单抗
英文名称	Risankizumab
英文别名	Immunoglobulin G1, anti-(human interleukin 23 subunit p19) (human-Mus musculus heavy chain), disulfide with human-Mus musculus κ-chain, dimer;Risankizumab
Cas No.	1612838-76-2
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Risankizumab (BI 655066) 是一种人源化 IgG 单克隆抗体，靶向 IL-23 p19 亚基(K_d <10 pM)，并能抑制人 IL-23 在小鼠脾细胞中诱导的 IL-17 产生(IC₅₀ = 2 pM)。Risankizumab 可用于研究免疫性和炎症性疾病，如寻常型银屑病、银屑病关节炎、广泛性脓疱型银屑病和红皮病型银屑病。

生物活性

Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (K d <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC 50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis.

性状

Liquid

IC50 & Target[1][2]

IL-23 <10 pM (Kd)

体外研究(In Vitro)

Risankizumab (BI 655066) has a high affinity for human and cynomolgus IL23 with Kds <10 pM.
Risankizumab (BI 655066) inhibits endogenous (THP-1 cell generated) human IL23-induced and recombinant cynomolgus IL23-induced IL17 production with IC50s of 2 pM and 17 pM, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Risankizumab (BI 655066) (1 mg/kg; i.p.; single dosage) inhibits IL23-induced mice ear swelling and cytokine production.
has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. McKeage K, Duggan S. Risankizumab: First Global Approval. Drugs. 2019 Jun;79(8):893-900.
[2]. Andrea Chiricozzi, et al. Risankizumab for the treatment of moderate to severe psoriasis. Expert Opinion on Biological Therapy. Volume 19, 2019 - Issue 1
[3]. Singh S, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel hi

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation